Soft Tissue Tumors of Uncertain Histogenesis

Buehler, Darya

doi:10.1007/978-1-4939-8812-9_12

Cited by 1 publication

(2 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, up to 20% of OFMTs lack ossifying tissue and are termed non-ossifying OFMTs. [2] Moreover, while more than two-thirds of OFMTs are positive for S-100 by immunohistochemistry, not all OFMT, including the case discussed in this report, demonstrate S-100 immunostaining [Table 1]. Typical OFMTs are more likely to express S-100 positivity than atypical and malignant OFMT, which further adds to the controversy of whether malignant OFMTs exist.…”

Section: Discussionmentioning

confidence: 82%

“…[1] While OFMTs most frequently occur in the subcutaneous soft tissues or skeletal muscles of the lower extremities, other common sites include the upper extremities, trunk, head and neck (mandible, nasal cavity, and paranasal sinuses), mediastinum, and breast. [2,5,10] ese tumors have historically been reported to present as slowly enlarging, well-circumscribed, painless masses attached to subcutaneous tendons, or muscle.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Malignant ossifying fibromyxoid tumor of the brain treated with post-operative fractionated stereotactic radiation therapy: A case report and literature review

Beyer

Sebastian

Prasad

et al. 2021

Surgical Neurology International

View full text Add to dashboard Cite

Background: Ossifying fibromyxoid tumor (OFMT) is a rare musculoskeletal soft-tissue neoplasm of uncertain histogenesis most frequently occurring in the lower extremities. Conventionally, considered benign, these tumors are often managed by surgical resection followed by surveillance. However, malignant OFMTs with an increased propensity for local recurrence and distant metastasis have been recently identified, and the role of adjuvant therapy in these more aggressive cases is unclear. Case Description: We present, to the best of our knowledge, the first reported case of a primary, malignant, and intracranial OFMT. A 29-year-old female presented with recurrent headaches secondary to a large mass in her right frontal lobe. She underwent gross total resection of the brain mass with final pathology consistent with malignant OFMT demonstrating high-risk features including increased cellularity, grade, and mitotic activity. Due to these high-risk features, she received postoperative fractionated stereotactic radiation therapy (FSRT) to the resection cavity, and to the best of our knowledge, she represents the only known patient with OFMT to be treated with adjuvant FSRT. She tolerated the adjuvant treatment well with no acute or late toxicities and remains disease-free over 5 ½ years after resection. Conclusion: Adjuvant FSRT appears to be a safe and efficacious approach for managing this rare intracranial disease presentation. We review this patient’s clinical course in the context of the literature to demonstrate the difficulties associated with accurate diagnosis of this rare tumor and the controversial role of adjuvant therapy in preventing disease recurrence in this patient population.

show abstract

Section: Discussionmentioning

confidence: 82%